Daily and Weekly “High Doses” of Cholecalciferol for the Prevention and Treatment of Vitamin D Deficiency for Obese or Multi-Morbidity and Multi-Treatment Patients Requiring Multi-Drugs—A Narrative Review
-
Published:2024-08-03
Issue:15
Volume:16
Page:2541
-
ISSN:2072-6643
-
Container-title:Nutrients
-
language:en
-
Short-container-title:Nutrients
Author:
Pludowski Pawel1ORCID, Marcinowska-Suchowierska Ewa23ORCID, Togizbayev Galymzhan4ORCID, Belaya Zhanna5ORCID, Grant William B.6ORCID, Pilz Stefan7ORCID, Holick Michael F.8ORCID
Affiliation:
1. Department of Clinical Biochemistry, The Children’s Memorial Health Institute, 04-730 Warsaw, Poland 2. Department of Internal Medicine and Geriatric Cardiology, Medical Centre of Postgraduate Education, 01-813 Warsaw, Poland 3. Department of Geriatrics and Gerontology, School of Public Health, Medical Centre of Postgraduate Education, 01-813 Warsaw, Poland 4. Department of Rheumatology, Kazakh National Medical University, 050000 Almaty, Kazakhstan 5. The National Medical Research Center for Endocrinology, 117036 Moscow, Russia 6. Sunlight, Nutrition and Health Research Center, San Francisco, CA 94109, USA 7. Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, 8036 Graz, Austria 8. Section Endocrinology, Diabetes, Nutrition and Weight Management, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
Abstract
Daily vitamin D supplementation using higher than normal dosing (up to the upper limit value) and intermittent (once or twice per week) dosing were studied in patients with increased risk of vitamin D deficiency. Using a PubMed database, a thorough search for published randomized controlled trials and other studies was conducted, and the results were analyzed. This review provides an overview of the use of 7000 IU daily, 30,000 IU per week or twice weekly, and 50,000 IU weekly of vitamin D for obtaining and maintaining 25(OH)D concentrations of at least 30 ng/mL in patients at high risk of vitamin D deficiency. The abovementioned dosages should be considered in adults with obesity, liver disease or malabsorption syndromes, or multi-diseased patients, mainly seniors requiring multi-drug treatment, including drugs affecting vitamin D metabolism. The simple schedules of 7000 IU/day, 30,000 IU/week or twice weekly, and 50,000 IU/week for use by patients with an increased risk of vitamin D deficiency were provided for consideration. Without monitoring of 25(OH)D, daily doses of 7000 IU or intermittent doses of 30,000 IU/week should be considered for a prolonged time as prophylactic or maintenance doses, mainly in obese patients, patients with liver disease and patients with malabsorption syndromes. For the treatment of possible vitamin D deficiency without assessment of 25(OH)D in these groups, intermittent doses of 30,000 IU twice weekly or 50,000 IU per week should be considered for a 6–8-week period only. The higher daily doses or the intermittent doses suggested above are effective, safe and responsive based on patient’s preferences.
Reference45 articles.
1. Płudowski, P., Kos-Kudła, B., Walczak, M., Fal, A., Zozulińska-Ziółkiewicz, D., Sieroszewski, P., Peregud-Pogorzelski, J., Lauterbach, R., Targowski, T., and Lewiński, A. (2023). Guidelines for Preventing and Treating Vitamin D Deficiency: A 2023 Update in Poland. Nutrients, 15. 2. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited;Holick;J. Clin. Endocrinol. Metab.,2012 3. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline;Demay;J. Clin. Endocrinol. Metab.,2024 4. Pludowski, P., Takacs, I., Boyanov, M., Belaya, Z., Diaconu, C.C., Mokhort, T., Zherdova, N., Rasa, I., Payer, J., and Pilz, S. (2022). Clinical Practice in the Prevention, Diagnosis and Treatment of Vitamin D Deficiency: A Central and Eastern European Expert Consensus Statement. Nutrients, 14. 5. NCD Risk Factor Collaboration (NCD-RisC) (2024). Worldwide trends in underweight and obesity from 1990 to 2022: A pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet, 403, 1027–1050.
|
|